Clinical trial
Comparative Bioavailability Study of a New GFT505 Formulation With the Existing One After 120 mg Single Oral GFT505 Administration and Assessment of the Gender Effect in Young Healthy Male and Female Volunteers Followed by a Single and Multiple Ascending Dose Safety, Tolerability and Pharmacokinetic Study of GFT505 in Overweight or Obese Subjects and in Diabetic Patients
NCT01474161 is registered in ClinicalTrials.gov with Genfit as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Comparative Bioavailability Study of a New GFT505 Formulation With the Existing One After 120 mg Single Oral GFT505 Administration and Assessment of the Gender Effect in Young Healthy Male and Female Volunteers Followed by a Single and Multiple Ascending Dose Safety, Tolerability and Pharmacokinetic Study of GFT505 in Overweight or Obese Subjects and in Diabetic Patients
- Lead sponsor
- Genfit
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- November 30, 2011
- Completion date
- November 30, 2012
- Enrollment
- 96 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
cardiovascular diseases, diabetes mellitus, type 2, dyslipidemia, metabolic diseases, obese, type 2 diabetes